Novo Nordisk A/S
5.2.2026 19:49:52 CET | Globenewswire | Press release
Share
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 5 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Liselotte Sofie Hyveled | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Member of the Board of Directors | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 0.00 | 1,085 | |||||
| d) | Aggregated information
| 1,085 shares DKK 0.00 | ||||
| e) | Date of the transaction | 2026-02-04 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | President and CEO | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 0.00 | 28,049 | |||||
| d) | Aggregated information
| 28,049 shares DKK 0.00 | ||||
| e) | Date of the transaction | 2026-02-04 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | David Moore | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, US Operations | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 0.00 | 23,895 | |||||
| d) | Aggregated information
| 23,895 shares DKK 0.00 | ||||
| e) | Date of the transaction | 2026-02-04 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | David Moore | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, US Operations | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares (to cover tax on shares transferred in accordance with Long Term Incentive programme) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 304.72 | 6,845 | |||||
| d) | Aggregated information
| 6,845 shares DKK 2,085,839.07 | ||||
| e) | Date of the transaction | 2026-02-04 | ||||
| f) | Place of the transaction | Nasdaq Copenhagen | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Emil Kongshøj Larsen | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, International Operations | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 0.00 | 7,289 | |||||
| d) | Aggregated information
| 7,289 shares DKK 0.00 | ||||
| e) | Date of the transaction | 2026-02-04 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Emil Kongshøj Larsen | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, International Operations | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares (to cover taxes transferred in accordance with Long Term Incentive programme) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 304.72 | 3,645 | |||||
| d) | Aggregated information
| 3,645 shares DKK 1,110,720.73 | ||||
| e) | Date of the transaction | 2026-02-04 | ||||
| f) | Place of the transaction | Nasdaq Copenhagen | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Tania Sabroe | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, People, Organisation & Corporate Affairs | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 0.00 | 11,562 | |||||
| d) | Aggregated information
| 11,562 shares DKK 0.00 | ||||
| e) | Date of the transaction | 2026-02-04 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Martin Holst Lange | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, R&D and Chief Scientific Officer (CSO) | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 0.00 | 23,092 | |||||
| d) | Aggregated information
| 23,092 shares DKK 0.00 | ||||
| e) | Date of the transaction | 2026-02-04 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Thilde Hummel Bøgebjerg | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, Enterprise IT & Quality | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 0.00 | 5,009 | |||||
| d) | Aggregated information
| 5,009 shares DKK 0.00 | ||||
| e) | Date of the transaction | 2026-02-04 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Karsten Munk Knudsen | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, Chief Financial Officer (CFO) | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 0.00 | 26,557 | |||||
| d) | Aggregated information
| 26,557 shares DKK 0.00 | ||||
| e) | Date of the transaction | 2026-02-04 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Kasper Bødker Mejlvang | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, CMC & Product Supply | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 0.00 | 6,706 | |||||
| d) | Aggregated information
| 6,706 shares DKK 0.00 | ||||
| e) | Date of the transaction | 2026-02-04 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, Product & Portfolio Strategy | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 0.00 | 21,075 | |||||
| d) | Aggregated information
| 21,075 shares DKK 0.00 | ||||
| e) | Date of the transaction | 2026-02-04 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
| Michael Novod +45 3075 6050 nvno@novonordisk.com | Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
| Max Ung +45 3077 6414 mxun@novonordisk.com | Sina Meyer +45 3079 6656 azey@novonordisk.com |
| Alex Bruce +45 34 44 26 13 axeu@novonordisk.com | Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com |
| Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
Company announcement No 07 / 2026
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Fortinet, Inc.5.2.2026 22:05:00 CET | Press release
Fortinet Reports Strong Fourth Quarter and Full Year 2025 Financial Results
BioPorto A/S5.2.2026 21:00:58 CET | Press release
BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update
BioPorto A/S5.2.2026 21:00:58 CET | Pressemeddelelse
BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopdatering
AI Producer Inc.5.2.2026 19:48:29 CET | Press release
AI Producer Secures Another U.S. Patent for AI-Assisted Live Event Production
NNIT A/S5.2.2026 18:10:48 CET | Press release
NNIT A/S: NNIT releases its annual report for 2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom